Supplementary Figure 2. Characterization of AIF1L expression in mouse tissues
a) Undetectable AIF1L expression in liver and heart b) Undetectable AIF1L protein and mRNA expression in skeletal muscle (immunoblotting for AIF1L using skeletal muscle lysates from both WT and AIF1L KO mice showed bands of ~14 and 17 kDa that are most likely non-specific. The global KO strategy used in this case is effective, as confirmed by the loss of signal for AIF1L in kidney, where the protein is highly expressed in WT animals -suggesting that these bands in the skeletal muscle samples are not due to AIF1L. RT-PCR analysis of skeletal muscle RNA using primers spanning exons 1 and 5 yielded the expected ~300 bp band in WT samples, but no products with KO, including potential transcripts that might arise from exon skipping events; in any case, such events in the recombined Aif1L allele would be expected to yield smaller products (as discussed in Methods), and would not explain the 17 kDa band.) c) Quantification of AIF1L expression in BAT and Brain d) Quantification of AIF1L expression in white adipose tissues Data are represented as mean ± SEM. ns -not significant.
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f Supplementary Figure 3 Modified Aif1l locus, tail DNA genotyping, and validation of loss of full length AIF1L a) As described by Wellcome Trust Sanger Institute (WTSI) The L1L2_Bact_P cassette was inserted at position 31961760 of Chromosome 2 upstream of the critical exon(s) (Build GRCm38). The cassette is composed of an FRT site followed by lacZ sequence and a loxP site. This first loxP site is followed by a neomycin resistance gene under the control of the human beta-actin promoter, SV40 polyadenylation cassette, a second FRT site and a second loxP site. A third loxP site is inserted downstream of the targeted exon(s) at position 31962560. The critical exon is thus flanked by loxP sites. b) Cre mediated recombination removes the neomycin cassette and exon 3, leaving one FRT site and lacZ, which is transcribed under the endogenous promoter of Aif1l. c) Tail DNA genotyping from mice WT, heterozygous, or homozygous for the modified Aif1l allele. d) End point PCR of Aif1l cDNA from WT (n = 2) and KO kidney (n = 2) with forward and reverse primers spanning exon 1 and exon 5, respectively. e) End point PCR of Aif1l cDNA from WT (n = 2) and KO kidney (n = 2) with forward and reverse primers spanning exon 1 and exon 2, respectively. f) Immunohistochemical (IHC) staining for AIF1L expression in kidney sections from 8-9-
week-old WT and AIF1L KO male mice.
Abbreviations for genotyping PCR-Mut-presence of modified allele, lacZ-presence of lacZ cassette, Cre-presence of Cre, WT-presence of Wild-type allele, Ex3-presence of exon 3 in the modified allele.
-- HFD for 18 weeks f) Leptin mRNA expression in adipose depots from male mice at baseline and upon long term HFD feeding and serum leptin levels at baseline (n=5 for WT and n=3 for KO) g,h) Adiponectin and resistin mRNA expression in adipose depots from male mice at baseline and upon long term HFD feeding (n=3) i) Whole body weight after 8, 10, 12, and 14 weeks of HFD feeding (n=11 for WT and n=8 for KO) Female mice on HFD for 16-18 weeks a) Total body weight curves of WT and KO mice fed high-fat diet starting at 8 weeks of age (n = 11 for WT, n = 13 for KO) b) Body weight, fat mass and lean mass measured by MRI at the end of HFD feeding period; age -26 weeks. (n = 7 for WT, n = 10 for KO) c) Food intake over 4 weeks (n = 5) d) Brown (BAT), inguinal subcutaneous (iSAT), peri-ovarian (poWAT) white adipose depot, and liver mass. (n = 7 for WT, n = 10 for KO) e) Gross appearance of tissues-representative images Data are represented as mean ± SEM. ns -not significant. Figure 7 Metabolic profile of WT and AIF1L deficient mice over a 24h period, upon short-and long-term HFD feeding a-c) Energy expenditure, RER, and Physical activity measurements over a 24 h period in metabolic cages for WT and KO mice fed HFD for 6 weeks (n = 3 for each genotype) d-f) Energy expenditure, RER, and Physical activity measurements over a 24 h period in metabolic cages for WT and KO mice fed HFD for 18 weeks (n = 3 for each genotype) Data are represented as mean ± SEM. ns-not significant. 
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